Cargando…

Comparison of neurotoxic potency between a novel chinbotulinumtoxinA with onabotulinumtoxinA, incobotulinumtoxinA and lanbotulinumtoxinA in rats

Four botulinumtoxin type A (BoNT/A) products, onabotulinumtoxinA (A/Ona), incobotulinumtoxinA (A/Inco), lanbotulinumtoxinA (A/Lan) and chinbotulinumtoxinA (A/Chin), are applied in the present study, among which A/Chin is newly produced. We aimed to compare the neurotoxic potency of these toxins by t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Ya, Liu, Wuchao, Pan, Lizhen, Jiang, Cong, Zhang, Chengxi, Lu, Yuxuan, Nie, Zhiyu, Jin, Lingjing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500563/ https://www.ncbi.nlm.nih.gov/pubmed/28721012 http://dx.doi.org/10.2147/DDDT.S138489

Ejemplares similares

Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin(®))
por: Dressler, Dirk, et al.
Publicado: (2013)

Real-World Dosing of OnabotulinumtoxinA and IncobotulinumtoxinA for Cervical Dystonia and Blepharospasm: Results from TRUDOSE and TRUDOSE II
por: Kent, Ruth, et al.
Publicado: (2021)

AbobotulinumtoxinA (Dysport(®)), OnabotulinumtoxinA (Botox(®)), and IncobotulinumtoxinA (Xeomin(®)) Neurotoxin Content and Potential Implications for Duration of Response in Patients
por: Field, Malgorzata, et al.
Publicado: (2018)

OnabotulinumtoxinA Displays Greater Biological Activity Compared to IncobotulinumtoxinA, Demonstrating Non-Interchangeability in Both In Vitro and In Vivo Assays
por: Rupp, David, et al.
Publicado: (2020)

Real-World Six-Year National Cost-Minimization Analysis of IncobotulinumtoxinA and OnabotulinumtoxinA in the VA/DoD Healthcare Systems
por: Kazerooni, Rashid, et al.
Publicado: (2021)

Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study
por: Rappl, Thomas, et al.
Publicado: (2013)

Correction: Field, M. et al. AbobotulinumtoxinA (Dysport(®)), OnabotulinumtoxinA (Botox(®)), and IncobotulinumtoxinA (Xeomin(®)) Neurotoxin Content and Potential Implications for Duration of Response in Patients
por: Field, Malgorzata, et al.
Publicado: (2019)

Profile of Xeomin(®) (incobotulinumtoxinA) for the treatment of blepharospasm
por: Park, Juwan, et al.
Publicado: (2011)

IncobotulinumtoxinA in aesthetics: Russian multidisciplinary expert consensus recommendations
por: Yutskovskaya, Yana, et al.
Publicado: (2015)

A Preclinical Study Comparing the Activity and Potency of OnabotulinumtoxinA and PrabotulinumtoxinA
por: Rupp, David C, et al.
Publicado: (2023)

Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity
por: Santamato, Andrea
Publicado: (2016)

Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm
por: Truong, Daniel D., et al.
Publicado: (2013)

Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders
por: Jost, Wolfgang H, et al.
Publicado: (2015)

Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI
por: Berweck, Steffen, et al.
Publicado: (2021)

Pooled Safety Analysis of IncobotulinumtoxinA in the Treatment of Neurological Disorders in Adults
por: Jost, Wolfgang H., et al.
Publicado: (2023)

Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia
por: Dressler, Dirk, et al.
Publicado: (2013)

Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines
por: Prager, Welf
Publicado: (2013)

SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea
por: Jost, Wolfgang H., et al.
Publicado: (2019)

Cost-Effectiveness of IncobotulinumtoxinA in the Treatment of Sialorrhea in Patients with Various Neurological Conditions
por: Makino, Koji, et al.
Publicado: (2020)

Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA
por: Fheodoroff, Klemens, et al.
Publicado: (2020)

Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Lower Limb Spasticity in Japanese Subjects
por: Masakado, Yoshihisa, et al.
Publicado: (2022)

A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia
por: Evidente, Virgilio Gerald H., et al.
Publicado: (2013)

One21: A Novel, Customizable Injection Protocol for Treatment of the Forehead with IncobotulinumtoxinA
por: de Sanctis Pecora, Carla
Publicado: (2020)

Pain Reduction in Cervical Dystonia Following Treatment with IncobotulinumtoxinA: A Pooled Analysis
por: Albanese, Alberto, et al.
Publicado: (2023)

OnabotulinumtoxinA in the treatment of neurogenic bladder
por: Gulamhusein, Aziz, et al.
Publicado: (2012)

OnabotulinumtoxinA for the treatment of overactive bladder
por: Cox, Lindsey, et al.
Publicado: (2014)

Botox (onabotulinumtoxinA) mechanism of action
por: Brin, Mitchell F., et al.
Publicado: (2023)

OnabotulinumtoxinA effects on trigeminal nociceptors
por: Moore, Ashley A, et al.
Publicado: (2023)

Prospective evaluation of incobotulinumtoxinA in the management of the masseter using two different injection techniques
por: Nikolis, Andreas, et al.
Publicado: (2018)

Effects of Ultrasound-Guided Administration of Botulinum Toxin (IncobotulinumtoxinA) in Patients with Lateral Epicondylitis
por: Galván Ruiz, Antonio, et al.
Publicado: (2019)

Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients
por: Eren, Ozan E., et al.
Publicado: (2020)

Pain Reduction in Adults with Limb Spasticity Following Treatment with IncobotulinumtoxinA: A Pooled Analysis
por: Wissel, Jörg, et al.
Publicado: (2021)

Safety Profile and Lack of Immunogenicity of IncobotulinumtoxinA in Pediatric Spasticity and Sialorrhea: A Pooled Analysis
por: Berweck, Steffen, et al.
Publicado: (2022)

Trigeminal neuralgia: IncobotulinumtoxinA (Xeomin), can it decrease the pharmacological intervention? (A case series)
por: Hosseini, Meghdad, et al.
Publicado: (2023)

Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin
por: Hefter, Harald, et al.
Publicado: (2022)

“Appropriate Treatment” and Therapeutic Window in Spasticity Treatment with IncobotulinumtoxinA: From 100 to 1000 Units
por: Ianieri, Giancarlo, et al.
Publicado: (2018)

Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study
por: Wissel, Jörg, et al.
Publicado: (2017)

The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®)
por: Morgante, Francesca, et al.
Publicado: (2019)

Pregnancy outcomes following exposure to onabotulinumtoxinA
por: Brin, Mitchell F., et al.
Publicado: (2015)

Cognitive effects of onabotulinumtoxinA in chronic migraine
por: Ho, Susan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_51a0burjheh6jq239l5qes2mtu